About Careers Internship MedBlog Contact us

HIV Vaccine Comes Closer to Reality

by VR Sreeraman on September 23, 2009 at 5:17 PM
 HIV Vaccine Comes Closer to Reality

A research team from The University of Texas, including an Indian origin scientist, has come closer to creating a vaccine for human immunodeficiency virus (HIV) by creating an antigen that induces protective antibodies capable of neutralizing genetically diverse HIV strains.

"The complexity of HIV has for long thwarted development of an effective HIV vaccine. Our findings open a new path toward an effective preventative and therapeutic vaccine," said Dr Sudhir Paul, the study's senior author and a professor in the Department of Pathology and Laboratory Medicine at The University of Texas Medical School at Houston.


"The new antigen is a prototype vaccine. This prototype successfully eliminates nature's restrictions on the production of broadly-neutralizing antibodies to HIV by the immune system," he added.

The vaccines work by introducing an antigen into the body, which spurs the immune system to produce antibodies that guard against infection.

Previously-tested HIV vaccine candidates stimulated vigorous production of antibodies to the mutable segments of the virus envelope. But, these vaccine candidates did not stimulate the production of antibodies to the regions essential for virus attachment to host T cells, the process that initiates infection.

In the new study, the researchers used a chemically-activated form of the HIV envelope protein gp120 to stimulate the production of mouse monoclonal antibodies that block infection of cultured human cells by genetically-diverse HIV strains from around the world.

Paul said these same antibodies can be found in humans who remain free of AIDS despite long-term HIV infection.

"Dr. Paul's team has developed a revolutionary antibody technology and used it to overcome major obstacles to a vaccine for HIV," said Dr Robert L. Hunter, professor and chairman of the Department of Pathology and Laboratory Medicine at the UT Medical School at Houston.

"They identified antibodies that neutralized 100 percent of strains drawn from the major viral subtypes.

"Furthermore, they have developed ways to immunize animals to produce them. No previous vaccine candidate has even approached these objectives," he added.

The study appears in the Journal of Biological Chemistry.

Source: ANI
Font : A-A+



Recommended Readings

Latest AIDS/HIV News

HIV Vaccine Clinical Trial Initiates in the United States and South Africa
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
Beauty Salon-Driven Initiative Boosts PrEP Awareness in Fight Against AIDS
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Immune-Evading HIV Protein Complex Solved
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Does Gender Influence Comorbidity Rates in HIV-Positive Smokers
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
Digital Test Measures HIV Viral Load
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

HIV Vaccine Comes Closer to Reality Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests